Search results
Results from the WOW.Com Content Network
Brent Saunders (1969 or 1970) is an American biopharma executive and entrepreneur who is the chairman and CEO of the health company Bausch & Lomb.He helped lead various mergers and acquisitions, including the mergers between Merck and Schering-Plough, the acquisition of Bausch + Lomb by Valeant Pharmaceuticals, and the $63 billion acquisition of Allergan by Abbvie.
Bausch & Lomb (since 2010 stylized as Bausch + Lomb[ 2]) is an American-Canadian eye health products company based in Vaughan, Ontario, Canada. It is one of the world's largest suppliers of contact lenses, [ 3] lens care products, pharmaceuticals, intraocular lenses, and other eye surgery products. [ 4][ 5] The company was founded in Rochester ...
Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals International, Inc.) is an American-Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health ...
By Euan Rocha and Rod Nickel TORONTO -- Valeant Pharmaceuticals International said on Monday it agreed to buy Bausch & Lomb Holdings Inc from Warburg Pincus LLC for $8.7 billion in cash, a deal ...
Quebec-based Valeant Pharmaceuticals and U.S.-based Bausch & Lomb have entered into a definitive agreement whereby Valeant will purchase privately held Bausch & Lomb for a total of $8.7 billion in ...
Bausch & Lomb Corp filed S-1 for its initial public offering, nearly 1.5 years after its parent company, Bausch Health Companies Inc (NYSE: BHC) said it would spin off the eye-care company.
In 1999, Bausch & Lomb sold Bushnell Performance Optics to the private equity firm Wind Point Partners through a recapitalization of Bushnell's then parent company, Worldwide Sports & Recreation. [3] [4] [5] The Serengeti Eyewear brand was acquired by Bushnell in September 2000. Bollé, Cébé and Serengeti Eyewear were part of Vista Outdoor's ...
The Bausch Health Thesis: The remaining company, after spinning off the B&L unit, will face “risk of multiple compression” as it is highly levered to Xifaxan, Gerberry said in the downgrade note.